Cargando…

Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma

The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Gestel, Dirk, Dragan, Tatiana, Grégoire, Vincent, Evans, Mererid, Budach, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081058/
https://www.ncbi.nlm.nih.gov/pubmed/32226773
http://dx.doi.org/10.3389/fonc.2020.00282
_version_ 1783508106915872768
author Van Gestel, Dirk
Dragan, Tatiana
Grégoire, Vincent
Evans, Mererid
Budach, Volker
author_facet Van Gestel, Dirk
Dragan, Tatiana
Grégoire, Vincent
Evans, Mererid
Budach, Volker
author_sort Van Gestel, Dirk
collection PubMed
description The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes many critical steps including interpretation of diagnostic imaging, image fusion, target volume delineation (tumor, lymph nodes, and organs at risk), and planning. Each step has become highly complex, and precise and rigorous QA throughout the planning process is essential. The ultimate aim is to precisely deliver radiation dose to the target, maximizing the tumor dose and minimizing the dose to surrounding organs at risk, in order to improve the therapeutic index. It is imperative that RT QA programs should systematically control all aspects of the RT planning pathway and include regular end-to-end tests and external audits. However, comprehensive QA should not be limited to RT and should, where possible, also be implemented for surgery, systemic therapy, pathology, as well as other aspects involved in the interdisciplinary treatment of HNC.
format Online
Article
Text
id pubmed-7081058
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70810582020-03-27 Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma Van Gestel, Dirk Dragan, Tatiana Grégoire, Vincent Evans, Mererid Budach, Volker Front Oncol Oncology The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes many critical steps including interpretation of diagnostic imaging, image fusion, target volume delineation (tumor, lymph nodes, and organs at risk), and planning. Each step has become highly complex, and precise and rigorous QA throughout the planning process is essential. The ultimate aim is to precisely deliver radiation dose to the target, maximizing the tumor dose and minimizing the dose to surrounding organs at risk, in order to improve the therapeutic index. It is imperative that RT QA programs should systematically control all aspects of the RT planning pathway and include regular end-to-end tests and external audits. However, comprehensive QA should not be limited to RT and should, where possible, also be implemented for surgery, systemic therapy, pathology, as well as other aspects involved in the interdisciplinary treatment of HNC. Frontiers Media S.A. 2020-03-12 /pmc/articles/PMC7081058/ /pubmed/32226773 http://dx.doi.org/10.3389/fonc.2020.00282 Text en Copyright © 2020 Van Gestel, Dragan, Grégoire, Evans and Budach. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Van Gestel, Dirk
Dragan, Tatiana
Grégoire, Vincent
Evans, Mererid
Budach, Volker
Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title_full Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title_fullStr Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title_short Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
title_sort radiotherapy quality assurance for head and neck squamous cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081058/
https://www.ncbi.nlm.nih.gov/pubmed/32226773
http://dx.doi.org/10.3389/fonc.2020.00282
work_keys_str_mv AT vangesteldirk radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma
AT dragantatiana radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma
AT gregoirevincent radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma
AT evansmererid radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma
AT budachvolker radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma